Indaptus Therapeutics, Inc.

As of June 17, 2025, Indaptus Therapeutics, Inc. is in a bearish trend with moderate strength, despite some mildly bullish signals from the weekly MACD, as bearish indicators dominate the technical landscape.

Indaptus Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $5.11 million. Key financial metrics indicate it is not profitable, with a negative P/E ratio and no dividend yield.

As of Jun 18, Indaptus Therapeutics, Inc. has a market capitalization of 5.11 million, with net sales of 0.00 million and a net profit of -15.75 million over the last four quarters. The company reported shareholder's funds of 3.94 million and total assets of 7.34 million as of Dec 24.